BHC Stock Chart & Stats
$4.43
$0.05(1.13%)
At close: 4:00 PM EDT
$4.43
$0.05(1.13%)
Day’s Range― - ―
52-Week Range$4.33 - $8.69
Previous Close$4.6
Volume1.72M
Average Volume (3M)2.52M
Market Cap
$2.25B
Enterprise Value$30.89K
Total Cash (Recent Filing)$1.30B
Total Debt (Recent Filing)$20.80B
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Oct 29, 2026EPS Estimate
1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.21
Shares Outstanding373,475,650
10 Day Avg. Volume1,780,128
30 Day Avg. Volume2,522,103
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-4.65
Price to Sales (P/S)0.25
P/FCF Ratio2.64
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$8.00Price Target Upside80.59% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)4.25
Revenue Forecast (FY)$10.58B
Bulls Say, Bears Say
Bulls Say
Company GuidanceCompany guidance exceeded prior analyst estimates, implying management expects stronger top-line growth than the market had anticipated.
Pipeline Opportunity — LarsucosterolInvestor focus on larsucosterol as a potential first approved treatment for severe alcohol-associated hepatitis could create a meaningful new commercial opportunity if regulatory approval is achieved.
Revenue And Product MixTotal revenue surpassed analysts' expectations driven by stronger vision-care sales, indicating diversification of revenue sources beyond core pharmaceuticals.
Bears Say
Clinical Trial SetbackPhase three RED-C program failing to meet its primary endpoint undermines prospects for the rifaximin asset and reduces expected contribution from new formulations.
Loss Of Exclusivity RiskLoss of exclusivity for Xifaxan represents a major revenue overhang that could materially reduce future sales without an immediate replacement product.
Profitability And Deal-making ConstraintsHigher selling and administrative expenses together with elevated interest costs and limited capital flexibility constrain the company's ability to pursue large business development deals and put pressure on profitability.
Bausch Health Companies News
BHC FAQ
What was Bausch Health Companies’s price range in the past 12 months?
Bausch Health Companies lowest stock price was $4.33 and its highest was $8.69 in the past 12 months.
What is Bausch Health Companies’s market cap?
Bausch Health Companies’s market cap is $2.25B.
When is Bausch Health Companies’s upcoming earnings report date?
Bausch Health Companies’s upcoming earnings report date is Oct 29, 2026 which is in 89 days.
How were Bausch Health Companies’s earnings last quarter?
Bausch Health Companies released its earnings results on Jul 29, 2026. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $0.994 by $0.265.
Is Bausch Health Companies overvalued?
According to Wall Street analysts Bausch Health Companies’s price is currently Undervalued.
Does Bausch Health Companies pay dividends?
Bausch Health Companies pays a Quarterly dividend of $1 which represents an annual dividend yield of N/A. See more information on Bausch Health Companies dividends here
What is Bausch Health Companies’s EPS estimate?
Bausch Health Companies’s EPS estimate is 1.22.
How many shares outstanding does Bausch Health Companies have?
Bausch Health Companies has 373,475,650 shares outstanding.
What happened to Bausch Health Companies’s price movement after its last earnings report?
Bausch Health Companies reported an EPS of $1.26 in its last earnings report, beating expectations of $0.994. Following the earnings report the stock price went up 28.846%.
Which hedge fund is a major shareholder of Bausch Health Companies?
Currently, no hedge funds are holding shares in BHC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bausch Health Companies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Company Description
Bausch Health Companies
Bausch Health Companies Inc. is a global healthcare enterprise dedicated to the creation, production, and sale of a diverse array of pharmaceutical, medical device, and over-the-counter items. Its primary therapeutic focus areas include eye health, digestive system issues, and dermatological conditions. The company's operations are strategically organized into five key divisions: Bausch + Lomb, which specializes in vision care, surgical solutions, and ophthalmic pharmaceuticals; Salix, concentrating on gastroenterology products within the United States; International Rx, offering a broad portfolio encompassing Solta products, branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across numerous international markets in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East; Ortho Dermatologics, providing dermatological products in the U.S. and Solta medical aesthetic devices globally; and Diversified Products, covering pharmaceutical products in neurology and other therapeutic classes, alongside generic and dentistry items in the United States. Previously known as Valeant Pharmaceuticals International, Inc., the company adopted its current name in July 2018 and maintains its headquarters in Laval, Canada.
BHC Company Deck
BHC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum with multiple quarters of consistent top-line and margin expansion, exceptional cash generation, meaningful net-debt reduction, and raised full-year guidance. Management flagged identifiable second-half headwinds (gross-to-net accruals, Aplenzin LOE, gradual Medicaid/340B erosion) and longer-term uncertainties (Xifaxan IP outcome, policy risks), but characterized many drivers of outperformance as transitional. Overall, the positive growth, margin improvement, cash flow strength, and upgraded guidance outweigh the listed challenges.View all BHC earnings summariesBHC Revenue Breakdown
47.34% Bausch + Lomb
25.69% Salix
12.23% International
10.77% Diversified Products
3.96% Solta Medical

BHC Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$8.00
▲(80.59% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Cronos Group
―
HLS Therapeutics Inc
―
DRI Healthcare
―
Ownership Overview
40.79% Insiders
2.88% Mutual Funds
0.22% Other Institutional Investors
49.99% Public Companies and
Individual Investors










